WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ: RGEN) today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%. Bioprocessing product revenue for the third quarter was $3,126,000 compared to $2,865,000 for the third quarter of fiscal 2010, an increase of $261,000 or 9%. Royalty and research revenue, which consisted of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia® and research grants, was $3,942,000 compared to $2,752,000 for the same quarter in the prior year. This increase was primarily due to $733,000 in grants that Repligen received under the Qualifying Therapeutic Discovery Project Program, which was created in March 2010 as part of The Patient Protection and Affordability Care Act.
